Affiliation:
1. From the Division of Hematology-Oncology, Department of Internal Medicine; Biostatistical Core, The Arthur G. James Comprehensive Cancer Center; and the Division of Medicinal Chemistry and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH
Abstract
PurposeNational Cancer Institute–sponsored Working Group (NCI-WG) response criteria for chronic lymphocytic leukemia (CLL) rely on physical examination, blood, and bone marrow evaluations. The widespread use of computed tomography (CT) scans has prompted many to advocate for the incorporation of this test into CLL response criteria.Patients and MethodsIn a retrospective review of 82 CLL patients treated at the Ohio State University (Columbus, OH), we compared CT assessed response using non-Hodgkin's lymphoma (NHL) response definitions with NCI-WG response.ResultsResponses by NCI-WG criteria included five complete responses (CRs), 32 partial responses (PRs), 21 patients with stable disease (SD), 17 patients with progressive disease (PD), and seven patients not assessable (NA). Responses by NHL-CT criteria included three CRs, 12 unconfirmed CRs (CRus), 16 PRs, 26 with SD, four with PD, and 21 NA. Using NCI-WG criteria, progression-free survival (PFS) was 27.3 months for CR and 11.4 months for PR. With NHL-CT criteria, PFS was 18.4 months for CR, 11.7 months for CRu, and 14.5 months for PR. In multivariate analysis, both NCI-WG and NHL-CT response correlated with PFS (P = .009 and .001, respectively).ConclusionCurrent NCI-WG CLL response criteria are a significant predictor of PFS in previously treated CLL patients, with no additional benefit from the inclusion of CT scans. Although retrospective, these results highlight the importance of prospective validation of CT scans before routine inclusion in CLL response criteria.
Publisher
American Society of Clinical Oncology (ASCO)
Reference21 articles.
1. Reis L, Harkins D, Krapcho M, et al: SEER Cancer Statistics Review , 1975-2003. Bethesda, MD, National Cancer Institute, 2005
2. Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study
3. Cherukuri A, Kadel E, Lee SH, et al: Human antagonistic anti-CD40 antibody, CHIR-12.12, inhibits CD40-mediated survival of chronic lymphocytic leukemia B cells leading to cellular apoptosis. Proc Am Soc Hematol 106:832,2005, (abstr 2965)
4. Kater AP, Dicker F, Fukuda T, et al: CD40-activation of chronic lymphocytic leukemia cells induces latent sensitivity to Fas/TRAIL-mediated apoptosis via a P53-independent, C-Abl-dependent pathway. Proc Am Soc Hematol 104:101,2004, (abstr 342)
5. Tong X, Georgakis GV, Li L, et al: In vitro activity of a novel fully human anti-CD40 antibody CHIR-12.12 in chronic lymphocytic leukemia: Blockade of CD40 activation and induction of ADCC. Proc Am Soc Hematol 104:686,2004, (abstr 2504)
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献